Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer
Introduction: In recent decades, pharmacoeconomic analysis of multiple diseases has significantly progressed; in particular, the most prevalent one is the cost-effectiveness analysis. Chemotherapy remains the leading and most effective treatment option for small cell lung cancer, which accounts for...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Belgorod National Research University
2023-07-01
|
| Series: | Research Results in Pharmacology |
| Subjects: | |
| Online Access: | https://rrpharmacology.ru/index.php/journal/article/view/376/420 https://rrpharmacology.ru/index.php/journal/article/view/376/364 |
| _version_ | 1797353867296374784 |
|---|---|
| author | Yelena A. Lunyova |
| author_facet | Yelena A. Lunyova |
| author_sort | Yelena A. Lunyova |
| collection | DOAJ |
| description | Introduction: In recent decades, pharmacoeconomic analysis of multiple diseases has significantly progressed; in particular, the most prevalent one is the cost-effectiveness analysis. Chemotherapy remains the leading and most effective treatment option for small cell lung cancer, which accounts for more than a quarter of all other forms of respiratory cancers.
Materials and Methods: An assessment of the incidence of lung cancer and its probable causes was carried out. The main methods used in the study were cost-of-treatment analysis, ABC/VEN analysis and cost-effectiveness analysis. Survival rates (number of years or months, interval and average number of years/ months) and the cost of a month of life were also evaluated.
Discussion: The results obtained on the basis of a questionnaire survey of patients with lung cancer demonstrate that smoking is the leading risk factor – 24.9% of the pro rata contribution. The author identified the most expensive drugs, costing 60-80% of the budget, that is scheme 2 ‘etoposide + carboplatin’, and the least expensive drugs, costing 5-10% of the budget, which are auxiliary drugs. According to the study results, patients managed following a chemotherapy regimen ‘etoposide + carboplatin’ have the highest survival rate at the highest cost of treatment compared to patients following a chemotherapy regimen ‘cyclophosphamide + doxorubicin + vincristine’, which is the least expensive.
Conclusion: Evidence-based comprehensive pharmacoeconomic model for evaluation of drug supply for chemotherapy in small cell lung cancer improves registration of history cases and allows for pharmacoeconomic cost-effectiveness analysis considering features of each patient. |
| first_indexed | 2024-03-08T13:37:11Z |
| format | Article |
| id | doaj.art-390a91978cf4413d96bc654dca015b28 |
| institution | Directory Open Access Journal |
| issn | 2658-381X |
| language | English |
| last_indexed | 2024-03-08T13:37:11Z |
| publishDate | 2023-07-01 |
| publisher | Belgorod National Research University |
| record_format | Article |
| series | Research Results in Pharmacology |
| spelling | doaj.art-390a91978cf4413d96bc654dca015b282024-01-16T15:22:05ZengBelgorod National Research UniversityResearch Results in Pharmacology2658-381X2023-07-01931910.18413/rrpharmacology.9.10037Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancerYelena A. Lunyova0https://orcid.org/0000-0002-6077-3043Voronezh State Medical University named after N.N. BurdenkoIntroduction: In recent decades, pharmacoeconomic analysis of multiple diseases has significantly progressed; in particular, the most prevalent one is the cost-effectiveness analysis. Chemotherapy remains the leading and most effective treatment option for small cell lung cancer, which accounts for more than a quarter of all other forms of respiratory cancers. Materials and Methods: An assessment of the incidence of lung cancer and its probable causes was carried out. The main methods used in the study were cost-of-treatment analysis, ABC/VEN analysis and cost-effectiveness analysis. Survival rates (number of years or months, interval and average number of years/ months) and the cost of a month of life were also evaluated. Discussion: The results obtained on the basis of a questionnaire survey of patients with lung cancer demonstrate that smoking is the leading risk factor – 24.9% of the pro rata contribution. The author identified the most expensive drugs, costing 60-80% of the budget, that is scheme 2 ‘etoposide + carboplatin’, and the least expensive drugs, costing 5-10% of the budget, which are auxiliary drugs. According to the study results, patients managed following a chemotherapy regimen ‘etoposide + carboplatin’ have the highest survival rate at the highest cost of treatment compared to patients following a chemotherapy regimen ‘cyclophosphamide + doxorubicin + vincristine’, which is the least expensive. Conclusion: Evidence-based comprehensive pharmacoeconomic model for evaluation of drug supply for chemotherapy in small cell lung cancer improves registration of history cases and allows for pharmacoeconomic cost-effectiveness analysis considering features of each patient.https://rrpharmacology.ru/index.php/journal/article/view/376/420 https://rrpharmacology.ru/index.php/journal/article/view/376/364small cell lung cancerchemotherapycost-effectivenesspharmacoeconomicsabc/ven analysiscost of the survived month |
| spellingShingle | Yelena A. Lunyova Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer Research Results in Pharmacology small cell lung cancer chemotherapy cost-effectiveness pharmacoeconomics abc/ven analysis cost of the survived month |
| title | Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer |
| title_full | Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer |
| title_fullStr | Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer |
| title_full_unstemmed | Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer |
| title_short | Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer |
| title_sort | pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer |
| topic | small cell lung cancer chemotherapy cost-effectiveness pharmacoeconomics abc/ven analysis cost of the survived month |
| url | https://rrpharmacology.ru/index.php/journal/article/view/376/420 https://rrpharmacology.ru/index.php/journal/article/view/376/364 |
| work_keys_str_mv | AT yelenaalunyova pharmacoeconomicevaluationofdrugsupplyforchemotherapyinsmallcelllungcancer |